Idiopathic Copper Deficiency Induced Myeloneuropathy
Mohammad Mousbah Al-Tabbaa1, Emily Horvath1
1Internal Medicine, University of Illinois College Medicine at Peoria, Peoria, USA.
Cureus
|October 25, 2021
Summary
Early recognition and treatment of copper deficiency can prevent irreversible neurologic damage. Prompt IV copper infusion successfully treated a patient with acute myeloneuropathy, improving symptoms and quality of life.
Area of Science:
- Neurology
- Nutritional Science
- Internal Medicine
Background:
- Idiopathic nutritional deficiencies, particularly copper deficiency, are often missed in patients without malabsorption history.
- These deficiencies can lead to severe and potentially irreversible neurological dysfunction.
Observation:
- A 45-year-old male presented with acute encephalopathy, myeloneuropathy, and urinary incontinence, initially presumed as acute inflammatory demyelinating polyradiculopathy (AIDP).
- Initial workup was non-revealing, and the patient did not respond to plasmapheresis.
- Further investigation revealed low copper levels (0.45 µg/dL), along with deficiencies in vitamins A, E, and B1.
Findings:
- Intravenous copper infusion therapy led to a significant clinical response.
- Repeat copper levels increased to 0.71 µg/dL post-treatment.
- The patient showed marked improvement in neurological symptoms, including wrist drop and sensory disturbances.
Implications:
- Copper deficiency, despite being a trace element, can cause significant neurological impairment.
- Early diagnosis and supplementation are crucial for neurological recovery and improved quality of life.
- This case highlights the importance of considering nutritional deficiencies in unexplained neurological presentations.
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
1.5K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.5K
Myasthenia Gravis: Overview and Treatment
2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K


